From The Industry Experts
-
Cell & Gene Therapies: An Overview Of FDA Regulatory Considerations For 2024
4/17/2024
This article outlines key FDA regulatory developments from the past few months relevant to sponsors seeking approval of cell and gene therapies in the U.S.
-
3 Steps For Internal Or Family Medicine Clinical Trials Enrollment
4/17/2024
If 25% of U.S. adults don’t have a primary care provider, how can you access enough patients to fill your internal or family medicine clinical trial? Here are 3 tips.
-
Patient Engagement: Early Cancer Detection Blood Draw
4/17/2024
Discover how we aided a pharmaceutical company in enrolling participants for a Phase III trial, DETECT-ASCEND 2, focused on Plasma-Based CancerSEEK Testing for early cancer detection.
-
Can Patient-Led Clinical Trial Design Save Neurology Research?
4/17/2024
What is causing high fail rates, and what are the best opportunities for sponsors to turn them around? See how understanding the factors can help sponsors navigate and improve outcomes in neurology clinical trials.
-
Comparative Effectiveness Of eConsent: Systematic Review
4/17/2024
This blog post examines eConsent vs. ICF on comprehension, acceptability, enrollment, retention, consent time, and site workload.
-
Exploring The Potential Of Non-Consumer Smartphones In Clinical Trials
4/17/2024
We selected and evaluated a non-consumer device, to explore its potential as a reliable tool for home-based ePRO measure administration. Here’s what we learned from this usability testing.
-
RTSM: Randomization And Cohort Management, IP Inventory Management
4/17/2024
Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.
-
Measuring Aspects Of Health In Heart Failure Research
4/17/2024
Dr. Bill Byrom sat with Cardiology Professor Marianna Fontana to discuss opportunities for measuring aspects of health meaningful for increasing the usefulness of COA measures in heart failure trials.
-
CDMO Support: Catalyst For Success In Early-Phase Drug Product Development And Manufacturing
4/17/2024
As sponsors strive to deliver therapies with increasing efficiency, CDMOs are poised to remain vital, offering specialized expertise, accelerated timelines, cost efficiency, and risk mitigation.
-
How To Determine Country Feasibility For Cell And Gene Therapy Clinical Trials
4/17/2024
Learn how to choose the right location — globally — for your next cell and gene therapy clinical trial.